Sfoglia per Autore
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial
2024-01-01 Kater, A. P.; Arslan, O.; Demirkan, F.; Herishanu, Y.; Ferhanoglu, B.; Diaz, M. G.; Leber, B.; Montillo, M.; Panayiotidis, P.; Rossi, D.; Skarbnik, A.; Tempescul, A.; Turgut, M.; Mellink, C. H.; van der Kevie-Kersemaekers, A. -M. F.; Lanham, S.; Sale, B.; Del Rio, L.; Popovic, R.; Chyla, B. J.; Busman, T.; Komlosi, V.; Wang, X.; Sail, K.; Pena, G. E.; Vizkelety, T.; Forconi, F.
The essential microenvironmental role of oligomannoses specifically inserted into the antigen-binding sites of lymphoma cells
2024-01-01 Stevenson, F. K.; Forconi, F.
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
2023-01-01 Hillmen, P.; Pitchford, A.; Bloor, A.; Broom, A.; Young, M.; Kennedy, B.; Walewska, R.; Furtado, M.; Preston, G.; Neilson, J. R.; Pemberton, N.; Sidra, G.; Morley, N.; Cwynarski, K.; Schuh, A.; Forconi, F.; Elmusharaf, N.; Paneesha, S.; Fox, C. P.; Howard, D. R.; Hockaday, A.; Brown, J. M.; Cairns, D. A.; Jackson, S.; Greatorex, N.; Webster, N.; Shingles, J.; Dalal, S.; Patten, P. E. M.; Allsup, D.; Rawstron, A.; Munir, T.
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
2023-01-01 Bonfiglio, S.; Sutton, L. -A.; Ljungstrom, V.; Capasso, A.; Pandzic, T.; Westrom, S.; Foroughi-Asl, H.; Skaftason, A.; Gellerbring, A.; Lyander, A.; Gandini, F.; Gaidano, G.; Trentin, L.; Bonello, L.; Reda, G.; Bodor, C.; Stavroyianni, N.; Tam, C. S.; Marasca, R.; Forconi, F.; Panayiotidis, P.; Ringshausen, I.; Jaksic, O.; Frustaci, A. M.; Iyengar, S.; Coscia, M.; Mulligan, S. P.; Ysebaert, L.; Strugov, V.; Pavlovsky, C.; Walewska, R.; Osterborg, A.; Cortese, D.; Ranghetti, P.; Baliakas, P.; Stamatopoulos, K.; Scarfo, L.; Rosenquist, R.; Ghia, P.
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia
2023-01-01 Moia, R.; Dondolin, R.; De Propris, M. S.; Talotta, D.; Mouhssine, S.; Perutelli, F.; Reda, G.; Mattiello, V.; Rigolin, G. M.; Motta, M.; Olivieri, J.; Fanin, R.; Perbellini, O.; Ferrarini, I.; Mauro, F. R.; Del Giudice, I.; Laurenti, L.; Tomasso, A.; Gentile, M.; Frustaci, A. M.; Tedeschi, A.; Gozzetti, A.; Stelitano, C.; Visco, C.; Moreno, C.; Forconi, F.; Marasca, R.; Coscia, M.; Rossi, D.; Foa, R.; Gaidano, G.
Development of a distributed international patient data registry for hairy cell leukemia
2022-01-01 Andritsos, L. A.; Anghelina, M.; Neal, J.; Blachly, J. S.; Mathur, P.; Lele, O.; Dearden, C.; Iyengar, S.; Cross, M.; Zent, C. S.; Rogers, K. A.; Epperla, N.; Lozanski, G.; Oakes, C. C.; Kraut, E.; Ruppert, A. S.; Zhao, Q.; Bhat, S. A.; Forconi, F.; Banerji, V.; Handunnetti, S.; Tam, C. S.; Seymour, J. F.; Else, M.; Kreitman, R. J.; Saven, A.; Call, T.; Parikh, S. A.; Ravandi, F.; Johnston, J. B.; Tiacci, E.; Troussard, X.; Tallman, M. S.; Dietrich, S.; Tadmor, T.; Gozzetti, A.; Zinzani, P. L.; Robak, T.; Quest, G.; Demeter, J.; Rai, K.; Fernandez, S. A.; Grever, M.
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia
2022-01-01 Ravandi, F.; Kreitman, R. J.; Tiacci, E.; Andritsos, L.; Banerji, V.; Barrientos, J. C.; Bhat, S. A.; Blachly, J. S.; Broccoli, A.; Call, T.; Chihara, D.; Dearden, C.; Demeter, J.; Dietrich, S.; Else, M.; Epperla, N.; Falini, B.; Forconi, F.; Gladstone, D. E.; Gozzetti, A.; Iyengar, S.; Johnston, J. B.; Jorgensen, J.; Juliusson, G.; Lauria, F.; Lozanski, G.; Parikh, S. A.; Park, J. H.; Polliack, A.; Quest, G.; Robak, T.; Rogers, K. A.; Saven, A.; Seymour, J. F.; Tadmor, T.; Tallman, M. S.; Tam, C. S.; Thompson, P. A.; Troussard, X.; Zent, C. S.; Zenz, T.; Zinzani, P. L.; Wormann, B.; Rai, K.; Grever, M.
High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
2022-01-01 Chiodin, G.; Drennan, S.; Martino, E. A.; Ondrisova, L.; Henderson, I.; del Rio, L.; Tracy, I.; D'Avola, A.; Parker, H.; Bonfiglio, S.; Scarfo, L.; Sutton, L. -A.; Strefford, J. C.; Forster, J.; Brake, O.; Potter, K. N.; Sale, B.; Lanham, S.; Mraz, M.; Ghia, P.; Stevenson, F. K.; Forconi, F.
Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia
2021-01-01 Lin, W. -Y.; Fordham, S. E.; Sunter, N.; Elstob, C.; Rahman, T.; Willmore, E.; Shepherd, C.; Strathdee, G.; Mainou-Fowler, T.; Piddock, R.; Mearns, H.; Barrow, T.; Houlston, R. S.; Marr, H.; Wallis, J.; Summerfield, G.; Marshall, S.; Pettitt, A.; Pepper, C.; Fegan, C.; Forconi, F.; Dyer, M. J. S.; Jayne, S.; Sellors, A.; Schuh, A.; Robbe, P.; Oscier, D.; Bailey, J.; Rais, S.; Bentley, A.; Cawkwell, L.; Evans, P.; Hillmen, P.; Pratt, G.; Allsup, D. J.; Allan, J. M.
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
2021-01-01 Grever, M.; Andritsos, L.; Banerji, V.; Barrientos, J. C.; Bhat, S.; Blachly, J. S.; Call, T.; Cross, M.; Dearden, C.; Demeter, J.; Dietrich, S.; Falini, B.; Forconi, F.; Gladstone, D. E.; Gozzetti, A.; Iyengar, S.; Johnston, J. B.; Juliusson, G.; Kraut, E.; Kreitman, R. J.; Lauria, F.; Lozanski, G.; Parikh, S. A.; Park, J.; Polliack, A.; Ravandi, F.; Robak, T.; Rogers, K. A.; Saven, A.; Seymour, J. F.; Tadmor, T.; Tallman, M. S.; Tam, C. S.; Tiacci, E.; Troussard, X.; Zent, C.; Zenz, T.; Zinzani, P. L.; Wormann, B.
Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior
2021-01-01 Chiodin, G.; Allen, J. D.; Bryant, D. J.; Rock, P.; Martino, E. A.; Valle-Argos, B.; Duriez, P. J.; Watanabe, Y.; Henderson, I.; Blachly, J. S.; Mccann, K. J.; Strefford, J. C.; Packham, G.; Geijtenbeek, T. B. H.; Figdor, C. G.; Wright, G. W.; Staudt, L. M.; Burack, R.; Bowden, T. A.; Crispin, M.; Stevenson, F. K.; Forconi, F.
Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V)
2020-01-01 Parry-Jones, N.; Joshi, A.; Forconi, F.; Dearden, C.
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study
2020-01-01 Owen, R. G.; Mccarthy, H.; Rule, S.; D'Sa, S.; Thomas, S. K.; Tournilhac, O.; Forconi, F.; Kersten, M. J.; Zinzani, P. L.; Iyengar, S.; Kothari, J.; Minnema, M. C.; Kastritis, E.; Aurran-Schleinitz, T.; Cheson, B. D.; Walter, H.; Greenwald, D.; Chen, D. -Y.; Frigault, M. M.; Hamdy, A.; Izumi, R.; Patel, P.; Wei, H.; Lee, S. K.; Mittag, D.; Furman, R. R.
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
2017-01-01 Grever, Michael R; Abdel Wahab, Omar; Andritsos, Leslie A; Banerji, Versha; Barrientos, Jacqueline; Blachly, James S; Call, Timothy G; Catovsky, Daniel; Dearden, Claire; Demeter, Judit; Else, Monica; Forconi, Francesco; Gozzetti, Alessandro; Ho, Anthony D; Johnston, James B; Jones, Jeffrey; Juliusson, Gunnar; Kraut, Eric; Kreitman, Robert J; Larratt, Loree; Lauria, Francesco; Lozanski, Gerard; Montserrat, Emili; Parikh, Sameer A; Park, Jae H; Polliack, Aaron; Quest, Graeme R; Rai, Kanti R; Ravandi, Farhad; Robak, Tadeusz; Saven, Alan; Seymour, John F; Tadmor, Tamar; Tallman, Martin S; Tam, Constantine; Tiacci, Enrico; Troussard, Xavier; Zent, Clive S; Zenz, Thorsten; Zinzani, Pier Luigi; Falini, Brunangelo
Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification
2017-01-01 Sutton, Lesley Ann; Hadzidimitriou, Anastasia; Baliakas, Panagiotis; Agathangelidis, Andreas; Langerak, Anton W; Stilgenbauer, Stephan; Pospisilova, Sarka; Davis, Zadie; Forconi, Francesco; Davi, Frederic; Ghia, Paolo; Rosenquist, Richard; Stamatopoulos, Kostas
Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide
2017-01-01 Maffei, Rossana; Fiorcari, Stefania; Martinelli, Silvia; Benatti, Stefania; Bulgarelli, Jenny; Rizzotto, Lara; Debbia, Giulia; Santachiara, Rita; Rigolin, Gian Matteo; Forconi, Francesco; Rossi, Davide; Laurenti, Luca; Palumbo, Giuseppe A.; Vallisa, Daniele; Cuneo, Antonio; Gaidano, Gianluca; Luppi, Mario; Marasca, Roberto
STING activation reverses lymphoma-mediated resistance to antibody immunotherapy
2017-01-01 Dahal, Lekh N; Dou, Lang; Hussain, Khiyam; Liu, Rena; Earley, Alexander; Cox, Kerry L; Murinello, Salome; Tracy, Ian; Forconi, Francesco; Steele, Andrew J; Duriez, Patrick; Gomez Nicola, Diego; Teeling, Jessica L; Glennie, Martin J; Cragg, Mark S; Beers, Stephen A.
The dual Syk/JAK inhibitor cerdulatinib antagonizes b-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia
2017-01-01 Blunt, Matthew D.; Koehrer, Stefan; Dobson, Rachel C.; Larrayoz, Marta; Wilmore, Sarah; Hayman, Alice; Parnell, Jack; Smith, Lindsay D.; Davies, Andrew; Johnson, Peter W. M.; Conley, Pamela B.; Pandey, Anjali; Strefford, Jonathan C.; Stevenson, Freda K.; Packham, Graham; Forconi, Francesco; Coffey, Greg P.; Burger, Jan A.; Steele, Andrew J.
PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis
2016-01-01 Carter, M. J; Cox, K. L; Blakemore, S. J; Turaj, A. H; Oldham, R. J; Dahal, L. N; Tannheimer, S; Forconi, Francesco; Packham, G; Cragg, M. S.
The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity
2016-01-01 Davis, Zadie; Forconi, Francesco; Parker, Anton; Gardiner, Anne; Thomas, Peter; Catovsky, Daniel; Rose Zerilli, Matthew; Strefford, Jonathan C; Oscier, David
| Titolo | Data di pubblicazione | Autore(i) | File | Abstract |
|---|---|---|---|---|
| Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial | 1-gen-2024 | Kater, A. P.; Arslan, O.; Demirkan, F.; Herishanu, Y.; Ferhanoglu, B.; Diaz, M. G.; Leber, B.; Montillo, M.; Panayiotidis, P.; Rossi, D.; Skarbnik, A.; Tempescul, A.; Turgut, M.; Mellink, C. H.; van der Kevie-Kersemaekers, A. -M. F.; Lanham, S.; Sale, B.; Del Rio, L.; Popovic, R.; Chyla, B. J.; Busman, T.; Komlosi, V.; Wang, X.; Sail, K.; Pena, G. E.; Vizkelety, T.; Forconi, F. | - | |
| The essential microenvironmental role of oligomannoses specifically inserted into the antigen-binding sites of lymphoma cells | 1-gen-2024 | Stevenson, F. K.; Forconi, F. | - | |
| Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial | 1-gen-2023 | Hillmen, P.; Pitchford, A.; Bloor, A.; Broom, A.; Young, M.; Kennedy, B.; Walewska, R.; Furtado, M.; Preston, G.; Neilson, J. R.; Pemberton, N.; Sidra, G.; Morley, N.; Cwynarski, K.; Schuh, A.; Forconi, F.; Elmusharaf, N.; Paneesha, S.; Fox, C. P.; Howard, D. R.; Hockaday, A.; Brown, J. M.; Cairns, D. A.; Jackson, S.; Greatorex, N.; Webster, N.; Shingles, J.; Dalal, S.; Patten, P. E. M.; Allsup, D.; Rawstron, A.; Munir, T. | - | |
| BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib | 1-gen-2023 | Bonfiglio, S.; Sutton, L. -A.; Ljungstrom, V.; Capasso, A.; Pandzic, T.; Westrom, S.; Foroughi-Asl, H.; Skaftason, A.; Gellerbring, A.; Lyander, A.; Gandini, F.; Gaidano, G.; Trentin, L.; Bonello, L.; Reda, G.; Bodor, C.; Stavroyianni, N.; Tam, C. S.; Marasca, R.; Forconi, F.; Panayiotidis, P.; Ringshausen, I.; Jaksic, O.; Frustaci, A. M.; Iyengar, S.; Coscia, M.; Mulligan, S. P.; Ysebaert, L.; Strugov, V.; Pavlovsky, C.; Walewska, R.; Osterborg, A.; Cortese, D.; Ranghetti, P.; Baliakas, P.; Stamatopoulos, K.; Scarfo, L.; Rosenquist, R.; Ghia, P. | - | |
| Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia | 1-gen-2023 | Moia, R.; Dondolin, R.; De Propris, M. S.; Talotta, D.; Mouhssine, S.; Perutelli, F.; Reda, G.; Mattiello, V.; Rigolin, G. M.; Motta, M.; Olivieri, J.; Fanin, R.; Perbellini, O.; Ferrarini, I.; Mauro, F. R.; Del Giudice, I.; Laurenti, L.; Tomasso, A.; Gentile, M.; Frustaci, A. M.; Tedeschi, A.; Gozzetti, A.; Stelitano, C.; Visco, C.; Moreno, C.; Forconi, F.; Marasca, R.; Coscia, M.; Rossi, D.; Foa, R.; Gaidano, G. | - | |
| Development of a distributed international patient data registry for hairy cell leukemia | 1-gen-2022 | Andritsos, L. A.; Anghelina, M.; Neal, J.; Blachly, J. S.; Mathur, P.; Lele, O.; Dearden, C.; Iyengar, S.; Cross, M.; Zent, C. S.; Rogers, K. A.; Epperla, N.; Lozanski, G.; Oakes, C. C.; Kraut, E.; Ruppert, A. S.; Zhao, Q.; Bhat, S. A.; Forconi, F.; Banerji, V.; Handunnetti, S.; Tam, C. S.; Seymour, J. F.; Else, M.; Kreitman, R. J.; Saven, A.; Call, T.; Parikh, S. A.; Ravandi, F.; Johnston, J. B.; Tiacci, E.; Troussard, X.; Tallman, M. S.; Dietrich, S.; Tadmor, T.; Gozzetti, A.; Zinzani, P. L.; Robak, T.; Quest, G.; Demeter, J.; Rai, K.; Fernandez, S. A.; Grever, M. | - | |
| Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia | 1-gen-2022 | Ravandi, F.; Kreitman, R. J.; Tiacci, E.; Andritsos, L.; Banerji, V.; Barrientos, J. C.; Bhat, S. A.; Blachly, J. S.; Broccoli, A.; Call, T.; Chihara, D.; Dearden, C.; Demeter, J.; Dietrich, S.; Else, M.; Epperla, N.; Falini, B.; Forconi, F.; Gladstone, D. E.; Gozzetti, A.; Iyengar, S.; Johnston, J. B.; Jorgensen, J.; Juliusson, G.; Lauria, F.; Lozanski, G.; Parikh, S. A.; Park, J. H.; Polliack, A.; Quest, G.; Robak, T.; Rogers, K. A.; Saven, A.; Seymour, J. F.; Tadmor, T.; Tallman, M. S.; Tam, C. S.; Thompson, P. A.; Troussard, X.; Zent, C. S.; Zenz, T.; Zinzani, P. L.; Wormann, B.; Rai, K.; Grever, M. | - | |
| High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL | 1-gen-2022 | Chiodin, G.; Drennan, S.; Martino, E. A.; Ondrisova, L.; Henderson, I.; del Rio, L.; Tracy, I.; D'Avola, A.; Parker, H.; Bonfiglio, S.; Scarfo, L.; Sutton, L. -A.; Strefford, J. C.; Forster, J.; Brake, O.; Potter, K. N.; Sale, B.; Lanham, S.; Mraz, M.; Ghia, P.; Stevenson, F. K.; Forconi, F. | - | |
| Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia | 1-gen-2021 | Lin, W. -Y.; Fordham, S. E.; Sunter, N.; Elstob, C.; Rahman, T.; Willmore, E.; Shepherd, C.; Strathdee, G.; Mainou-Fowler, T.; Piddock, R.; Mearns, H.; Barrow, T.; Houlston, R. S.; Marr, H.; Wallis, J.; Summerfield, G.; Marshall, S.; Pettitt, A.; Pepper, C.; Fegan, C.; Forconi, F.; Dyer, M. J. S.; Jayne, S.; Sellors, A.; Schuh, A.; Robbe, P.; Oscier, D.; Bailey, J.; Rais, S.; Bentley, A.; Cawkwell, L.; Evans, P.; Hillmen, P.; Pratt, G.; Allsup, D. J.; Allan, J. M. | - | |
| Hairy cell leukemia and COVID-19 adaptation of treatment guidelines | 1-gen-2021 | Grever, M.; Andritsos, L.; Banerji, V.; Barrientos, J. C.; Bhat, S.; Blachly, J. S.; Call, T.; Cross, M.; Dearden, C.; Demeter, J.; Dietrich, S.; Falini, B.; Forconi, F.; Gladstone, D. E.; Gozzetti, A.; Iyengar, S.; Johnston, J. B.; Juliusson, G.; Kraut, E.; Kreitman, R. J.; Lauria, F.; Lozanski, G.; Parikh, S. A.; Park, J.; Polliack, A.; Ravandi, F.; Robak, T.; Rogers, K. A.; Saven, A.; Seymour, J. F.; Tadmor, T.; Tallman, M. S.; Tam, C. S.; Tiacci, E.; Troussard, X.; Zent, C.; Zenz, T.; Zinzani, P. L.; Wormann, B. | - | |
| Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior | 1-gen-2021 | Chiodin, G.; Allen, J. D.; Bryant, D. J.; Rock, P.; Martino, E. A.; Valle-Argos, B.; Duriez, P. J.; Watanabe, Y.; Henderson, I.; Blachly, J. S.; Mccann, K. J.; Strefford, J. C.; Packham, G.; Geijtenbeek, T. B. H.; Figdor, C. G.; Wright, G. W.; Staudt, L. M.; Burack, R.; Bowden, T. A.; Crispin, M.; Stevenson, F. K.; Forconi, F. | - | |
| Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V) | 1-gen-2020 | Parry-Jones, N.; Joshi, A.; Forconi, F.; Dearden, C. | - | |
| Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study | 1-gen-2020 | Owen, R. G.; Mccarthy, H.; Rule, S.; D'Sa, S.; Thomas, S. K.; Tournilhac, O.; Forconi, F.; Kersten, M. J.; Zinzani, P. L.; Iyengar, S.; Kothari, J.; Minnema, M. C.; Kastritis, E.; Aurran-Schleinitz, T.; Cheson, B. D.; Walter, H.; Greenwald, D.; Chen, D. -Y.; Frigault, M. M.; Hamdy, A.; Izumi, R.; Patel, P.; Wei, H.; Lee, S. K.; Mittag, D.; Furman, R. R. | - | |
| Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia | 1-gen-2017 | Grever, Michael R; Abdel Wahab, Omar; Andritsos, Leslie A; Banerji, Versha; Barrientos, Jacqueline; Blachly, James S; Call, Timothy G; Catovsky, Daniel; Dearden, Claire; Demeter, Judit; Else, Monica; Forconi, Francesco; Gozzetti, Alessandro; Ho, Anthony D; Johnston, James B; Jones, Jeffrey; Juliusson, Gunnar; Kraut, Eric; Kreitman, Robert J; Larratt, Loree; Lauria, Francesco; Lozanski, Gerard; Montserrat, Emili; Parikh, Sameer A; Park, Jae H; Polliack, Aaron; Quest, Graeme R; Rai, Kanti R; Ravandi, Farhad; Robak, Tadeusz; Saven, Alan; Seymour, John F; Tadmor, Tamar; Tallman, Martin S; Tam, Constantine; Tiacci, Enrico; Troussard, Xavier; Zent, Clive S; Zenz, Thorsten; Zinzani, Pier Luigi; Falini, Brunangelo | - | |
| Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification | 1-gen-2017 | Sutton, Lesley Ann; Hadzidimitriou, Anastasia; Baliakas, Panagiotis; Agathangelidis, Andreas; Langerak, Anton W; Stilgenbauer, Stephan; Pospisilova, Sarka; Davis, Zadie; Forconi, Francesco; Davi, Frederic; Ghia, Paolo; Rosenquist, Richard; Stamatopoulos, Kostas | - | |
| Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide | 1-gen-2017 | Maffei, Rossana; Fiorcari, Stefania; Martinelli, Silvia; Benatti, Stefania; Bulgarelli, Jenny; Rizzotto, Lara; Debbia, Giulia; Santachiara, Rita; Rigolin, Gian Matteo; Forconi, Francesco; Rossi, Davide; Laurenti, Luca; Palumbo, Giuseppe A.; Vallisa, Daniele; Cuneo, Antonio; Gaidano, Gianluca; Luppi, Mario; Marasca, Roberto | - | |
| STING activation reverses lymphoma-mediated resistance to antibody immunotherapy | 1-gen-2017 | Dahal, Lekh N; Dou, Lang; Hussain, Khiyam; Liu, Rena; Earley, Alexander; Cox, Kerry L; Murinello, Salome; Tracy, Ian; Forconi, Francesco; Steele, Andrew J; Duriez, Patrick; Gomez Nicola, Diego; Teeling, Jessica L; Glennie, Martin J; Cragg, Mark S; Beers, Stephen A. | - | |
| The dual Syk/JAK inhibitor cerdulatinib antagonizes b-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia | 1-gen-2017 | Blunt, Matthew D.; Koehrer, Stefan; Dobson, Rachel C.; Larrayoz, Marta; Wilmore, Sarah; Hayman, Alice; Parnell, Jack; Smith, Lindsay D.; Davies, Andrew; Johnson, Peter W. M.; Conley, Pamela B.; Pandey, Anjali; Strefford, Jonathan C.; Stevenson, Freda K.; Packham, Graham; Forconi, Francesco; Coffey, Greg P.; Burger, Jan A.; Steele, Andrew J. | - | |
| PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis | 1-gen-2016 | Carter, M. J; Cox, K. L; Blakemore, S. J; Turaj, A. H; Oldham, R. J; Dahal, L. N; Tannheimer, S; Forconi, Francesco; Packham, G; Cragg, M. S. | - | |
| The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity | 1-gen-2016 | Davis, Zadie; Forconi, Francesco; Parker, Anton; Gardiner, Anne; Thomas, Peter; Catovsky, Daniel; Rose Zerilli, Matthew; Strefford, Jonathan C; Oscier, David | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile